LEVOFLOXACIN- levofloxacin_tablet, film coated
Function and Efficacy
Levofloxacin is a member of the fluoroquinolone class of antibacterial agents [see Microbiology (12. 4) The mean +/- SD pharmacokinetic parameters of levofloxacin determined under single and steady-state conditions following administration of the oral tablets, are summarized in Table 8. Table 8: Mean +/- SD Levofloxacin PK Parameters Regimen C max T max (h) AUC (mcgh/mL) CL/F 1 Vd/F 2 (L) t 1/2 (h) CL R Single dose 250 mg oral tablet 3 2. 9 156 +/- 20 ND 7. 9 142 +/- 21 500 mg oral tablet 3* 5. 8 178 +/- 28 ND 6. 6 103 +/- 30 750 mg oral tablet 4* 9. 8 101 +/- 20 129 +/- 24 83 +/- 17 7. 9 ND Multiple dose 500 mg every 24h oral tablet 3 5. 7 175 +/- 25 102 +/- 22 7. 6 116 +/- 31 750 mg every 24h oral tablet 4 8. 6 143 +/- 29 100 +/- 16 8. 5 116 +/- 28 500 mg oral tablet single dose, effects of gender and age: Male 5 5. 9 166 +/- 44 89 +/- 13 7. 1 126 +/- 38 Female 6 7 +/- 1. 2 136 +/- 44 62 +/- 16 6. 8 106 +/- 40 Young 7 5. 8 182 +/- 35 83 +/- 18 6 +/- 0. 9 140 +/- 33 Elderly 8 7 +/- 1. 3 121 +/- 33 67 +/- 19 7. 6 +/- 2 91 +/- 29 500 mg oral single dose tablet, patients with renal impairment: CLCR 50 to 80 mL/min 7. 8 88 +/- 10 ND 9. 9 57 +/- 8 CLCR 20 to 49 mL/min 7. 6 51 +/- 19 ND 27 +/- 10 26 +/- 13 CLCR <20 mL/min 8. 1 +/- 1 263. 5 33 +/- 8 ND 35 +/- 5 13 +/- 3 Hemodialysis 5. 2 ND ND ND 76 +/- 42 ND CAPD 6. 1 ND ND ND 51 +/- 24 ND 1 2 3 4 5 6 7 8 * Absolute bioavailability; F=0. 08 from a 500 mg tablet and F=0. 06 from a 750 mg tablet; ND=not determined. Absorption Levofloxacin is rapidly and essentially completely absorbed after oral administration. Peak plasma concentrations are usually attained one to two hours after oral dosing. The absolute bioavailability of levofloxacin from a 500 mg tablet and a 750 mg tablet of levofloxacin The plasma concentration profile of levofloxacin after IV administration is similar and comparable in extent of exposure (AUC) to that observed for levofloxacin tablets when equal doses (mg/mg) are administered. Therefore, the oral and IV routes of administration can be considered interchangeable. Distribution The mean volume of distribution of levofloxacin generally ranges from 74 to 112 L after single and multiple 500 mg or 750 mg doses, indicating widespread distribution into body tissues. Levofloxacin reaches its peak levels in skin tissues and in blister fluid of healthy subjects at approximately 3 hours after dosing. The skin tissue biopsy to plasma AUC ratio is approximately 2 and the blister fluid to plasma AUC ratio is approximately 1 following multiple once-daily oral administration of 750 mg and 500 mg doses of levofloxacin, respectively, to healthy subjects. Levofloxacin also penetrates well into lung tissues. Lung tissue concentrations were generally 2- to 5-fold higher than plasma concentrations and ranged from approximately 2. 3 mcg/g over a 24-hour period after a single 500 mg oral dose. In vitro Elimination Levofloxacin is stereochemically stable in plasma and urine and does not invert metabolically to its enantiomer, D-ofloxacin. Levofloxacin undergoes limited metabolism in humans and is primarily excreted as unchanged drug in the urine. Following oral administration, approximately 87% of an administered dose was recovered as unchanged drug in urine within 48 hours, whereas less than 4% of the dose was recovered in feces in 72 hours. Less than 5% of an administered dose was recovered in the urine as the desmethyl and N-oxide metabolites, the only metabolites identified in humans. These metabolites have little relevant pharmacological activity. Excretion Levofloxacin is excreted largely as unchanged drug in the urine. The mean terminal plasma elimination half-life of levofloxacin ranges from approximately 6 to 8 hours following single or multiple doses of levofloxacin given orally or intravenously. The mean apparent total body clearance and renal clearance range from approximately 144 to 226 mL/min and 96 to 142 mL/min, respectively. Renal clearance in excess of the glomerular filtration rate suggests that tubular secretion of levofloxacin occurs in addition to its glomerular filtration. Concomitant administration of either cimetidine or probenecid results in approximately 24% and 35% reduction in the levofloxacin renal clearance, respectively, indicating that secretion of levofloxacin occurs in the renal proximal tubule. No levofloxacin crystals were found in any of the urine samples freshly collected from subjects receiving levofloxacin. Specific Populations Geriatric Patients There are no significant differences in levofloxacin pharmacokinetics between young and elderly subjects when the subjects’ differences in creatinine clearance are taken into consideration. Following a 500 mg oral dose of levofloxacin to healthy elderly subjects (66 to 80 years of age), the mean terminal plasma elimination half-life of levofloxacin was about 7. 6 hours, as compared to approximately 6 hours in younger adults. The difference was attributable to the variation in renal function status of the subjects and was not believed to be clinically significant. Drug absorption appears to be unaffected by age. Levofloxacin [see Use in Specific Populations (8. Pediatric Patients The pharmacokinetics of levofloxacin following a single 7 mg/kg intravenous dose were investigated in pediatric patients ranging in age from 6 months to 16 years. Pediatric patients cleared levofloxacin faster than adult patients, resulting in lower plasma exposures than adults for a given mg/kg dose. Subsequent pharmacokinetic analyses predicted that a dosage regimen of 8 mg/kg every 12 hours (not to exceed 250 mg per dose) for pediatric patients 6 months to 17 years of age would achieve comparable steady state plasma exposures (AUC 0-24 max [see Dosage and Administration (2. 2) ] Male and Female Subjects There are no significant differences in levofloxacin pharmacokinetics between male and female subjects when subjects’ differences in creatinine clearance are taken into consideration. Following a 500 mg oral dose of levofloxacin to healthy male subjects, the mean terminal plasma elimination half-life of levofloxacin was about 7. 5 hours, as compared to approximately 6. 1 hours in female subjects. This difference was attributable to the variation in renal function status of the male and female subjects and was not believed to be clinically significant. Drug absorption appears to be unaffected by the gender of the subjects. Dose adjustment based on gender alone is not necessary. Racial or Ethnic Groups The effect of race on levofloxacin pharmacokinetics was examined through a covariate analysis performed on data from 72 subjects: 48 white and 24 non-white. The apparent total body clearance and apparent volume of distribution were not affected by the race of the subjects. Patients with Renal Impairment Clearance of levofloxacin is substantially reduced and plasma elimination half-life is substantially prolonged in adult patients with impaired renal function (creatinine clearance < 50 mL/min), requiring dosage adjustment in such patients to avoid accumulation. Neither hemodialysis nor continuous ambulatory peritoneal dialysis (CAPD) is effective in removal of levofloxacin from the body, indicating that supplemental doses of levofloxacin are not required following hemodialysis or CAPD [see Dosage and Administration (2. 3) Use in Specific Populations (8. 6) Patients with Hepatic Impairment Pharmacokinetic studies in hepatically impaired patients have not been conducted. Due to the limited extent of levofloxacin metabolism, the pharmacokinetics of levofloxacin are not expected to be affected by hepatic impairment [see Use in Specific Populations (8. 7) Patients with Bacterial Infection The pharmacokinetics of levofloxacin in patients with serious community-acquired bacterial infections are comparable to those observed in healthy subjects. Drug Interaction Studies [see Drug Interactions (7) Mechanism of Action Levofloxacin is the L-isomer of the racemate, ofloxacin, a quinolone antimicrobial agent. The antibacterial activity of ofloxacin resides primarily in the L-isomer. The mechanism of action of levofloxacin and other fluoroquinolone antimicrobials involves inhibition of bacterial topoisomerase IV and DNA gyrase (both of which are type II topoisomerases), enzymes required for DNA replication, transcription, repair and recombination. Fluoroquinolone resistance can arise through mutations in defined regions of DNA gyrase or topoisomerase IV, termed the Quinolone-Resistance Determining Regions (QRDRs), or through altered efflux. Fluoroquinolones, including levofloxacin, differ in chemical structure and mode of action from aminoglycosides, macrolides and beta-lactam antibiotics, including penicillins. Fluoroquinolones may, therefore, be active against bacteria resistant to these antimicrobials. Resistance to levofloxacin due to spontaneous mutation in vitro -9 -10 Levofloxacin has in vitro Levofloxacin has been shown to be active against most isolates of the following bacteria both in vitro Indications and Usage (1) Staphylococcus aureus Staphylococcus epidermidis Staphylococcus saprophyticus Streptococcus pneumoniae 1 Streptococcus pyogenes 1 Streptococcus pneumoniae nd Gram-Negative Bacteria Escherichia coli Haemophilus influenzae Haemophilus parainfluenzae Klebsiella pneumoniae Legionella pneumophila Moraxella catarrhalis Proteus mirabilis Pseudomonas aeruginosa Serratia marcescens Other microorganisms Mycoplasma pneumoniae in vitro but their clinical significance is unknown. in vitro beta-hemolytic Streptococcus (Group C/F) beta - Streptococcus (Group G) Streptococcus agalactiae Streptococcus milleri Viridans group streptococci Bacillus anthracis Acinetobacter lwoffii Bordetella pertussis Citrobacter koseri Citrobacter freundii Enterobacter aerogenes Enterobacter sakazakii Klebsiella oxytoca Morganella morganii Pantoea agglomerans Proteus vulgaris Providencia rettgeri Providencia stuartii Pseudomonas fluorescens Yersinia pestis Anaerobic bacteria Susceptibility Tests For specific information regarding susceptibility test interpretive criteria and associated test methods and quality control standards recognized by FDA for this drug, please see: https://www.
Indication
Levofloxacin tablets are a fluoroquinolone antibacterial indicated in adults (18 years of age and older) with infections caused by designated, susceptible bacteria and in pediatric patients where indicated ( 1 12. 4 Pneumonia: Nosocomial ( 1. 3 Skin and Skin Structure Infections (SSSI): Complicated ( 1. 5 Chronic bacterial prostatitis ( 1. 6 Inhalational Anthrax, Post-Exposure in adult and pediatric patients ( 1. 7 Plague in adult and pediatric patients ( 1. 8 Urinary Tract Infections (UTI): Complicated ( 1. 12 Acute Pyelonephritis ( 1. 11 Acute Bacterial Exacerbation of Chronic Bronchitis ( 1. 13 Acute Bacterial Sinusitis ( 1. 15 Levofloxacin tablets are indicated in adult patients for the treatment of nosocomial pneumonia due to methicillin-susceptible Staphylococcus aureus, Pseudomonas aeruginosa, Serratia marcescens, Escherichia coli, Klebsiella pneumoniae, Haemophilus influenzae, Streptococcus pneumoniae Pseudomonas aeruginosa [see Clinical Studies (14. 1) Levofloxacin tablets are indicated in adult patients for the treatment of community-acquired pneumonia due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae Streptococcus pneumoniae Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Chlamydophila pneumoniae, Legionella pneumophila, Mycoplasma pneumoniae [see Dosage and Administration (2. 1) and Clinical Studies (14. MDRSP isolates are isolates resistant to two or more of the following antibacterials: penicillin (MIC >=2 mcg/mL), 2 nd Levofloxacin tablets are indicated in adult patients for the treatment of community-acquired pneumonia due to Streptococcus pneumoniae Haemophilus influenzae, Haemophilus parainfluenzae, Mycoplasma pneumoniae, Chlamydophila pneumoniae [see Dosage and Administration (2. Levofloxacin tablets are indicated in adult patients for the treatment of complicated skin and skin structure infections due to methicillin-susceptible Staphylococcus aureus, Enterococcus faecalis, Streptococcus pyogenes, Proteus mirabilis [see Clinical Studies (14. Levofloxacin tablets are indicated in adult patients for the treatment of uncomplicated skin and skin structure infections (mild to moderate) including abscesses, cellulitis, furuncles, impetigo, pyoderma, wound infections, due to methicillin-susceptible Staphylococcus aureus, Streptococcus pyogenes Levofloxacin tablets are indicated in adult patients for the treatment of chronic bacterial prostatitis due to Escherichia coli, Enterococcus faecalis, Staphylococcus epidermidis [see Clinical Studies (14. 6) Levofloxacin tablets are indicated for inhalational anthrax (post-exposure) to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis [see Dosage and Administration (2. 2) [see Clinical Studies (14. 9) Levofloxacin tablets are indicated for treatment of plague, including pneumonic and septicemic plague, due to Yersinia pestis Y. pestis [see Dosage and Administration (2. 2)] Efficacy studies of levofloxacin tablets could not be conducted in humans with plague for ethical and feasibility reasons. Therefore, approval of this indication was based on an efficacy study conducted in animals [see Clinical Studies (14. 10) Levofloxacin tablets are indicated in adult patients for the treatment of complicated urinary tract infections due to Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis [see Clinical Studies (14. Levofloxacin tablets are indicated in adult patients for the treatment of complicated urinary tract infections (mild to moderate) due to Enterococcus faecalis, Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa [see Clinical Studies (14. 8) ] Levofloxacin tablets are indicated in adult patients for the treatment of acute pyelonephritis caused by Escherichia coli [see Clinical Studies (14. 8 Levofloxacin tablets are indicated in adult patients for the treatment of uncomplicated urinary tract infections (mild to moderate) due to Escherichia coli, Klebsiella pneumoniae, Staphylococcus saprophyticus Because fluoroquinolones, including levofloxacin tablets, have been associated with serious adverse reactions [see Warnings and Precautions (5. 15) Levofloxacin tablets are indicated in adult patients for the treatment of acute bacterial exacerbation of chronic bronchitis (ABECB) due to methicillin-susceptible Staphylococcus aureus Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella catarrhalis Because fluoroquinolones, including levofloxacin tablets, have been associated with serious adverse reactions [see Warnings and Precautions (5. 15) Levofloxacin tablets are indicated in adult patients for the treatment of acute bacterial sinusitis (ABS) due to Streptococcus pneumoniae Haemophilus influenzae, Moraxella catarrhalis [see Clinical Studies (14. 4) Because fluoroquinolones, including levofloxacin tablets, have been associated with serious adverse reactions [see Warnings and Precautions (5. 15) To reduce the development of drug-resistant bacteria and maintain the effectiveness of levofloxacin tablets and other antibacterial drugs, levofloxacin tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Culture and susceptibility testing Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to levofloxacin [see Microbiology (12. 4) As with other drugs in this class, some isolates of Pseudomonas aeruginosa.
Usage and Dosage
Administer levofloxacin tablets to pediatric patients weighing 30 kg and greater only (2. 2 Levofloxacin tablets cannot be administered to pediatric patients who weigh less than 30 kg because of the limitations of the available strengths. Alternative formulations of levofloxacin may be considered for pediatric patients who weigh less than 30 kg (2. 2 Dosage in Adult and Pediatric Patients with Creatinine Clearance greater than or equal to 50 mL/minute (2. 2 Type of Infection Dose Every 24 hours Duration (days) Nosocomial Pneumonia (1. 1) 750 mg 7 to 14 Community Acquired Pneumonia (1. 2) 500 mg 7 to 14 Community Acquired Pneumonia (1. 3) 750 mg 5 Complicated SSSI (1. 4) 750 mg 7 to 14 Uncomplicated SSSI (1. 5) 500 mg 7 to 10 Chronic Bacterial Prostatitis (1. 6) 500 mg 28 Inhalational Anthrax (Post-Exposure) (1. 2 Plague (1. 2 Complicated UTI (1. 11 750 mg 5 Complicated UTI ( 1. 11 250 mg 10 Uncomplicated UTI (1. 12) 250 mg 3 Acute Bacterial Exacerbation of Chronic Bronchitis (1. 13) 500 mg 7 Acute Bacterial Sinusitis (1. 14) 750 mg 5 500 mg 10 to 14 Adjust dose for creatinine clearance less than 50 mL/minute ( 2. 3 The usual dose of levofloxacin tablets is 250 mg, 500 mg, or 750 mg administered orally every 24 hours, as indicated by infection and described in Table 1. These recommendations apply to patients with creatinine clearance >= 50 mL/minute. For patients with creatinine clearance less than 50 mL/min, adjustments to the dosing regimen are required [see Dosage and Administration (2. 3)] Table 1: Dosage of Levofloxacin Tablets in Adult Patients with Creatinine Clearance greater than or equal to 50 mL/minute) Type of Infection * Dosed Every 24 hours Duration (days) dagger Nosocomial Pneumonia 750 mg 7 to 14 Community Acquired Pneumonia double dagger 500 mg double dagger 7 to 14 double dagger Community Acquired Pneumonia section 750 mg section 5 section Complicated Skin and Skin Structure Infections (SSSI) 750 mg 7 to 14 Uncomplicated SSSI 500 mg 7 to 10 Chronic Bacterial Prostatitis 500 mg 28 Inhalational Anthrax (Post-Exposure), adult and pediatric patients weighing 50 kg Þ,ß Þ,ß 500 mg 60 ß ß Plague, adult and pediatric patients weighing 50 kg à 500 mg 10 to 14 Complicated Urinary Tract Infection (cUTI) or paragraph 750 mg 5 Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) # 250 mg # 10 # Uncomplicated Urinary Tract Infection 250 mg 3 Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB) 500 mg 7 Acute Bacterial Sinusitis (ABS) 750 mg 5 500 mg 10 to 14 * [see Indications and Usage (1) dagger double dagger Staphylococcus aureus, Streptococcus pneumoniae Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Chlamydophila pneumoniae, Legionella pneumophila, Mycoplasma pneumoniae [see Indications and Usage (1. 2 section Streptococcus pneumoniae Haemophilus influenzae, Haemophilus parainfluenzae, Mycoplasma pneumoniae, or Chlamydophila pneumoniae [see Indications and Usage (1. 3) paragraph Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis E. coli, # Enterococcus faecalis, Enterococcus cloacae, Escherichia coli Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa E. anthracis [see Clinical Studies (14. 9 ß [see Warnings and Precautions (5. 12) Use in Specific Populations (8. 4 Clinical Studies (14. 9) à Yersinia pestis The dosage of levofloxacin tablets for inhalational anthrax (post-exposure) and plague in pediatric patients who weigh 30 kg or greater is described below in Table 2. Levofloxacin tablets cannot be administered to patients who weigh less than 30 kg because of the limitations of the available strength. Alternative formulations of levofloxacin may be considered for pediatric patients who weigh less than 30 kg. Table 2: Levofloxacin Tablets Dosage in Pediatric Patients Weighing 30 kg or greater with Inhalational Anthrax (Post-Exposure) and Plague* Type of Infection * Dose Frequency Duration dagger Inhalational Anthrax (post-exposure) double dagger,section Pediatric patients weighing 50 kg or greater 500 mg every 24 hours 60 days section Pediatric patients weighing 30 kg to less than 50 kg 250 mg every 12 hours 60 days section Plague paragraph Pediatric patients weighing 50 kg or greater 500 mg every 24 hours 10 to 14 days Pediatric patients weighing 30 kg to less than 50 kg every 12 hours 10 to 14 days * Bacillus anthracis [see Indications and Usage (1. 13) Yersinia pestis [ see Indications and Usage (1. 14) ] dagger double dagger B. anthracis section [see Warnings and Precautions (5. 4) Clinical Studies (14. 9) Yersinia pestis Administer levofloxacin tablets with caution in patients with renal impairment. Careful clinical observation and appropriate laboratory studies should be performed prior to and during therapy since elimination of levofloxacin may be reduced in these patients. [see Use in Specific Populations (8. 6) Table 3: Dosage Adjustment in Adult Patients with Renal Impairment (Creatinine Clearance less than 50 mL/minute) Creatinine Clearance greater than or equal to 50 mL/minute Creatinine Creatinine Hemodialysis or 750 mg every 48 hours 750 mg initial dose, then 750 mg initial dose, then 500 mg initial dose, then 500 mg initial dose, then 500 mg initial dose, then No dosage adjustment 250 mg every 48 hours. No information on Levofloxacin tablets should be administered at least two hours before or two hours after antacids containing magnesium, aluminum, as well as sucralfate, metal cations such as iron, and multivitamin preparations with zinc or didanosine chewable/buffered tablets or the pediatric powder for oral solution [see Drug Interactions (7. 1) and Patient Counseling Information (17) Levofloxacin tablets can be administered without regard to food. If patients miss a dose, they should take it as soon as possible anytime up to 8 hours prior to their next scheduled dose. If less than 8 hours remain before the next dose, wait until their next scheduled dose. Adequate hydration of patients receiving levofloxacin tablets should be maintained to prevent the formation of highly concentrated urine. Crystalluria and cylindruria have been reported with quinolones [see Adverse Reactions (6) and Patient Counseling Information (17).
Label
Adverse Reactions
WARNING: SERIOUS ADVERSE REACTIONS INCLUDING TENDINITIS,TENDON RUPTURE, PERIPHERAL NEUROPATHY, CENTRAL NERVOUS SYSTEM EFFECTS AND EXACERBATION OF MYASTHENIA GRAVIS
Fluoroquinolones, including levofloxacin, have been associated with disabling and potentially irreversible serious adverse reactions that have occurred together [see Warnings and Precautions (5. 1) Tendinitis and tendon rupture [see Warnings and Precautions (5. 2) Peripheral neuropathy [see Warnings and Precautions (5. 3) Central nervous system effects [see Warnings and Precautions (5. 4) Discontinue levofloxacin immediately and avoid the use of fluoroquinolones, including levofloxacin, in patients who experience any of these serious adverse reactions [see Warnings and Precautions (5. 1) Fluoroquinolones, including levofloxacin, may exacerbate muscle weakness in patients with myasthenia gravis. Avoid levofloxacin in patients with a known history of myasthenia gravis [see Warnings and Precautions (5. 5) Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5. 15) Uncomplicated urinary tract infection [see Indications and Usage (1. 12) Acute bacterial exacerbation of chronic bronchitis [see Indications and Usage (1. 13) Acute bacterial sinusitis [see Indications and Usage (1. WARNING: SERIOUS ADVERSE REACTIONS INCLUDING TENDINITIS, TENDON RUPTURE, PERIPHERAL NEUROPATHY, CENTRAL NERVOUS SYSTEM EFFECTS AND EXACERBATION OF MYASTHENIA GRAVIS See full prescribing information for complete boxed warning. Fluoroquinolones, including levofloxacin, have been associated with disabling and potentially irreversible serious adverse reactions that have occurred together ( 5. 1 Tendinitis and tendon rupture ( 5. 2 Peripheral neuropathy ( 5. 3 Central nervous system effects ( 5. 4 Discontinue levofloxacin immediately and avoid the use of fluoroquinolones, including levofloxacin, in patients who experience any of these serious adverse reactions ( 5. 1 Fluoroquinolones, including levofloxacin, may exacerbate muscle weakness in patients with myasthenia gravis. 5) Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions ( 5. 15 Uncomplicated urinary tract infection ( 1. 12 Acute bacterial exacerbation of chronic bronchitis ( 1. 13 Acute bacterial sinusitis ( 1.
ADVERSE REACTIONS
The following serious and otherwise important adverse drug reactions are discussed in greater detail in other sections of labeling: Disabling and Potentially Irreversible Serious Adverse Reactions [see Warnings and Precautions (5. 1) Tendinitis and Tendon Rupture [see Warnings and Precautions (5. 2) Peripheral Neuropathy [see Warnings and Precautions (5. 3) Central Nervous System Effects [see Warnings and Precautions (5. 4) Exacerbation of Myasthenia Gravis [see Warnings and Precautions (5. 5) Other Serious and Sometimes Fatal Reactions [see Warnings and Precautions (5. 6) Hypersensitivity Reactions [see Warnings and Precautions (5. 7) Hepatotoxicity [see Warnings and Precautions (5. 8) Risk of Aortic Aneurysm and Dissection [see Warnings and Precautions (5. 9) Clostridium difficile [see Warnings and Precautions (5. 10) Prolongation of the QT Interval [see Warnings and Precautions (5. 11) Musculoskeletal Disorders in Pediatric Patients [see Warnings and Precautions (5. 12) Blood Glucose Disturbances [see Warnings and Precautions (5. 13) Photosensitivity/Phototoxicity [see Warnings and Precautions (5. 14) Development of Drug Resistant Bacteria [see Warnings and Precautions (5. 15) Crystalluria and cylindruria have been reported with quinolones, including levofloxacin. Therefore, adequate hydration of patients receiving levofloxacin should be maintained to prevent the formation of a highly concentrated urine [see Dosage and Administration (2. The most common reactions (>=3%) were nausea, headache, diarrhea, insomnia, constipation and dizziness ( 6. 1 To report SUSPECTED ADVERSE REACTIONS, contact Aurobindo Pharma USA, Inc. at 1-866-850-2876 or FDA at 1-800-FDA-1088 or www. gov/medwatch. Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The data described below reflect exposure to levofloxacin in 7537 patients in 29 pooled Phase 3 clinical trials. The population studied had a mean age of 50 years (approximately 74% of the population was < 65 years of age), 50% were male, 71% were Caucasian, 19% were Black. Patients were treated with levofloxacin for a wide variety of infectious diseases [see Indications and Usage (1) The overall incidence, type and distribution of adverse reactions was similar in patients receiving levofloxacin doses of 750 mg once daily, 250 mg once daily, and 500 mg once or twice daily. Discontinuation of levofloxacin due to adverse drug reactions occurred in 4. 3% of patients overall, 3. 8% of patients treated with the 250 mg and 500 mg doses and 5. 4% of patients treated with the 750 mg dose. The most common adverse drug reactions leading to discontinuation with the 250 and 500 mg doses were gastrointestinal (1. 4%), primarily nausea (0. 6%); vomiting (0. 4%); dizziness (0. 3%); and headache (0. The most common adverse drug reactions leading to discontinuation with the 750 mg dose were gastrointestinal (1. 2%), primarily nausea (0. 6%), vomiting (0. 5%); dizziness (0. Adverse reactions occurring in >=1% of levofloxacin-treated patients and less common adverse reactions, occurring in 0. 1 to <1% of levofloxacin-treated patients, are shown in Table 4 and Table 5, respectively. The most common adverse drug reactions (>=3%) are nausea, headache, diarrhea, insomnia, constipation, and dizziness. Table 4: Common (>=1%) Adverse Reactions Reported in Clinical Trials with Levofloxacin # System/Organ Class Adverse Reaction % (N = 7537) Infections and Infestations moniliasis 1 Psychiatric Disorders insomnia * [see Warnings and Precautions (5. 4) 4 Nervous System Disorders headache [see Warnings and Precautions (5. 4) 6 Respiratory, Thoracic and Mediastinal Disorders dyspnea [see Warnings and Precautions (5. 7) 1 Gastrointestinal Disorders nausea 7 Skin and Subcutaneous Tissue Disorders rash [see Warnings and Precautions (5. 7) 2 Reproductive System and Breast Disorders Vaginitis 1 dagger General Disorders and Administration Site Conditions edema 1 * dagger # Table 5: Less Common (0. 1 to 1%) Adverse Reactions Reported in Clinical Trials with Levofloxacin (N = 7537) System/Organ Class Adverse Reaction Infections and Infestations genital moniliasis Blood and Lymphatic System Disorders anemia [see Warnings and Precautions (5. 6) Immune System Disorders allergic reaction [see Warnings and Precautions (5. 7) Metabolism and Nutrition Disorders hyperglycemia [see Warnings and Precautions (5. 13) Psychiatric Disorders anxiety * [see Warnings and Precautions (5. 4) * * Nervous System Disorders tremor [see Warnings and Precautions (5. 4) [see Warnings and Precautions (5. 3) * Respiratory, Thoracic and Mediastinal Disorders epistaxis Cardiac Disorders cardiac arrest Vascular Disorders phlebitis Gastrointestinal Disorders gastritis C. difficile [see Warnings and Precautions (5. 10) Hepatobiliary Disorders abnormal hepatic function Skin and Subcutaneous Tissue Disorders urticaria [see Warnings and Precautions (5. 7) Musculoskeletal and Connective Tissue Disorders arthralgia [see Warnings and Precautions (5. 2) Renal and Urinary Disorders abnormal renal function [see Warnings and Precautions (5. 6) * In clinical trials using multiple-dose therapy, ophthalmologic abnormalities, including cataracts and multiple punctate lenticular opacities, have been noted in patients undergoing treatment with quinolones, including levofloxacin. The relationship of the drugs to these events is not presently established. Table 6 lists adverse reactions that have been identified during post-approval use of levofloxacin. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Table 6: Postmarketing Reports Of Adverse Drug Reactions System/Organ Class Adverse Reaction Blood and Lymphatic System Disorders pancytopenia [see Warnings and Precautions (5. 6) Immune System Disorders hypersensitivity reactions, sometimes fatal including: [see Warnings and Precautions (5. 7) Psychiatric Disorders psychosis [see Warnings and Precautions (5. 4) Nervous System Disorders exacerbation of myasthenia gravis [see Warnings and Precautions (5. 5) [see Warnings and Precautions (5. 3) [see Warnings and Precautions (5. 4) Eye Disorders uveitis Ear and Labyrinth Disorders hypoacusis Cardiac Disorders isolated reports of torsade de pointes [see Warnings and Precautions (5. 11) Vascular Disorders vasodilatation Respiratory, Thoracic and Mediastinal Disorders isolated reports of allergic pneumonitis [see Warnings and Precautions (5. 6) Hepatobiliary Disorders hepatic failure (including fatal cases) [see Warnings and Precautions (5. 8) Skin and Subcutaneous Tissue Disorders bullous eruptions to include: [see Warnings and Precautions (5. 6) [see Warnings and Precautions (5. 14) Musculoskeletal and Connective Tissue Disorders tendon rupture [see Warnings and Precautions (5. 2) Renal and Urinary Disorders interstitial nephritis [see Warnings and Precautions (5. 6) General Disorders and Administration Site Conditions multi-organ failure Investigations prothrombin time prolonged.
Precautions
Levofloxacin tablets are contraindicated in persons with known hypersensitivity to levofloxacin, or other quinolone antibacterials [see Warnings and Precautions (5. 3) Known hypersensitivity to levofloxacin tablets or other quinolones (4 5.
Special Population Medication
Geriatrics: (5. 5 17 Pediatrics: 5. 10 Lactation: Risk Summary (see Data) Data Risk Summary Published literature reports that levofloxacin is present in human milk following intravenous and oral administration ( see Data see Use in Specific Populations (8. 4) Clinical Pharmacology (12. 3) However, for inhalation anthrax (post exposure), during an incident resulting in exposure to anthrax, the risk-benefit assessment of continuing breastfeeding while the mother (and potentially the infant) is (are) on levofloxacin may be acceptable [see Dosage and Administration (2. 2) Pediatric Use (8. 4) Clinical Studies (14. 2) Data A published literature reports that peak levofloxacin human milk concentration was 8. 2 mg/L at 5 hours after dosing in a woman who received 500 mg of intravenous, followed by oral, levofloxacin daily. For an infant fed exclusively with human milk (approximately 900 mL/day), an estimated maximum daily dose of levofloxacin through breastfeeding is 5 mg (i. , approximately 1% of maternal daily dose). The above data come from a single case and may not be generalizable to the general population of lactating women. Quinolones, including levofloxacin, cause arthropathy and osteochondrosis in juvenile animals of several species. [see Warnings and Precautions (5. 12) and Animal Toxicology and/or Pharmacology (13. 2) ] Inhalational Anthrax (Post-Exposure) Levofloxacin is indicated in pediatric patients 6 months of age and older, for inhalational anthrax (post-exposure). The risk-benefit assessment indicates that administration of levofloxacin to pediatric patients is appropriate. The safety of levofloxacin in pediatric patients treated for more than 14 days has not been studied [see Indications and Usage (1. 7) , Dosage and Administration (2. 2) and Clinical Studies (14. Plague Levofloxacin is indicated in pediatric patients, 6 months of age and older, for treatment of plague, including pneumonic and septicemic plague due to Yersinia pestis Y. pestis [see Indications and Usage (1. 8) , Dosage and Administration (2. Safety and effectiveness of levofloxacin tablets in pediatric patients below the age of six months have not been established. Pharmacokinetics following intravenous administration The pharmacokinetics of levofloxacin following a single intravenous dose were investigated in pediatric patients ranging in age from six months to 16 years. Pediatric patients cleared levofloxacin faster than adult patients resulting in lower plasma exposures than adults for a given mg/kg dose [see Clinical Pharmacology (12. 3) Clinical Studies (14. 9) Dosage in Pediatric Patients with Inhalational Anthrax or Plague For the recommended levofloxacin tablet dosage in pediatric patients with inhalational anthrax or plague, see Dosage and Administration (2. Levofloxacin tablets cannot be administered to pediatric patients who weigh less than 30 kg because of the limitations of the available strengths. Alternative formulations of levofloxacin may be considered for pediatric patients who weigh less than 30 kg. Adverse Reactions In clinical trials, 1534 pediatric patients (6 months to 16 years of age) were treated with oral and intravenous levofloxacin. Pediatric patients 6 months to 5 years of age received levofloxacin 10 mg/kg twice a day and pediatric patients greater than 5 years of age received 10 mg/kg once a day (maximum 500 mg per day) for approximately 10 days. Levofloxacin tablets can only be administered to pediatric patients with inhalational anthrax (post-exposure) or plague who are 30 kg or greater due to the limitations of the available strengths [see Dosage and Administration (2. 2) A subset of pediatric patients in the clinical trials (1340 levofloxacin-treated and 893 non-fluoroquinolone-treated) enrolled in a prospective, long-term surveillance study to assess the incidence of protocol-defined musculoskeletal disorders (arthralgia, arthritis, tendinopathy, gait abnormality) during 60 days and 1 year following the first dose of the study drug. Pediatric patients treated with levofloxacin had a significantly higher incidence of musculoskeletal disorders when compared to the non-fluoroquinolone-treated children as illustrated in Table 7. 2) Table 7: Incidence of Musculoskeletal Disorders in Pediatric Clinical Trial Follow-up Period Levofloxacin N = 1340 Non-Fluoroquinolone * N = 893 p-value dagger 60 days 28 (2. 038 1 year double dagger 46 (3. 025 * dagger double dagger Arthralgia was the most frequently occurring musculoskeletal disorder in both treatment groups. Most of the musculoskeletal disorders in both groups involved multiple weight-bearing joints. Disorders were moderate in 8/46 (17%) children and mild in 35/46 (76%) levofloxacin-treated pediatric patients and most were treated with analgesics. The median time to resolution was 7 days for levofloxacin-treated pediatric patients and 9 for non-fluoroquinolone-treated children (approximately 80% resolved within 2 months in both groups). No pediatric patient had a severe or serious disorder and all musculoskeletal disorders resolved without sequelae. Vomiting and diarrhea were the most frequently reported adverse reactions, occurring in similar frequency in the levofloxacin-treated and non-fluoroquinolone-treated pediatric patients. In addition to the adverse reactions reported in pediatric patients in clinical trials, adverse reactions reported in adults during clinical trials or post-marketing experience [see Adverse Reactions (6) Geriatric patients are at increased risk for developing severe tendon disorders including tendon rupture when being treated with a fluoroquinolone such as levofloxacin. This risk is further increased in patients receiving concomitant corticosteroid therapy. Tendinitis or tendon rupture can involve the Achilles, hand, shoulder, or other tendon sites and can occur during or after completion of therapy; cases occurring up to several months after fluoroquinolone treatment have been reported. Caution should be used when prescribing levofloxacin to elderly patients especially those on corticosteroids. Patients should be informed of this potential side effect and advised to discontinue levofloxacin and contact their healthcare provider if any symptoms of tendinitis or tendon rupture occur [see Boxed Warning Warnings and Precautions (5. 2) ; and Adverse Reactions (6. 2) ] In Phase 3 clinical trials, 1,945 levofloxacin-treated patients (26%) were >= 65 years of age. Of these, 1,081 patients (14%) were between the ages of 65 and 74 and 864 patients (12%) were 75 years or older. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, but greater sensitivity of some older individuals cannot be ruled out. Severe, and sometimes fatal, cases of hepatotoxicity have been reported post-marketing in association with levofloxacin. The majority of fatal hepatotoxicity reports occurred in patients 65 years of age or older and most were not associated with hypersensitivity. Levofloxacin should be discontinued immediately if the patient develops signs and symptoms of hepatitis [see Warnings and Precautions (5. Epidemiologic studies report an increased rate of aortic aneurysm and dissection within two months following use of fluoroquinolones, particularly in elderly patients [see Warnings and Precautions (5. 9) Elderly patients may be more susceptible to drug-associated effects on the QT interval. Therefore, precaution should be taken when using levofloxacin with concomitant drugs that can result in prolongation of the QT interval (e. , Class IA or Class III antiarrhythmics) or in patients with risk factors for torsade de pointes (e. , known QT prolongation, uncorrected hypokalemia) [see Warnings and Precautions (5. 11) [see Clinical Pharmacology (12. Clearance of levofloxacin is substantially reduced and plasma elimination half-life is substantially prolonged in patients with renal impairment (creatinine clearance < 50 mL/min), requiring dosage adjustment in such patients to avoid accumulation. Neither hemodialysis nor continuous ambulatory peritoneal dialysis (CAPD) is effective in removal of levofloxacin from the body, indicating that supplemental doses of levofloxacin are not required following hemodialysis or CAPD [see Dosage and Administration (2. 3) Pharmacokinetic studies in patients with hepatic impairment have not been conducted. Due to the limited extent of levofloxacin metabolism, the pharmacokinetics of levofloxacin are not expected to be affected by hepatic impairment.
Drug Interactions
Interacting Drug Interaction Multivalent cation-containing products including antacids, metal cations or didanosine Absorption of levofloxacin is decreased when the tablets are taken within 2 hours of these products. 1) Warfarin Effect may be enhanced. Monitor prothrombin time, INR and watch for bleeding (7. 2) Antidiabetic agents Carefully monitor blood glucose ( 5. 3) While the chelation by divalent cations is less marked than with other fluoroquinolones, concurrent administration of levofloxacin tablets with antacids containing magnesium, or aluminum, as well as sucralfate, metal cations such as iron, and multivitamin preparations with zinc may interfere with the gastrointestinal absorption of levofloxacin, resulting in systemic levels considerably lower than desired. Tablets with antacids containing magnesium, aluminum, as well as sucralfate, metal cations such as iron, and multivitamin preparations with zinc or didanosine may substantially interfere with the gastrointestinal absorption of levofloxacin, resulting in systemic levels considerably lower than desired. These agents should be taken at least two hours before or two hours after oral levofloxacin administration. No significant effect of levofloxacin on the peak plasma concentrations, AUC, and other disposition parameters for R- and S- warfarin was detected in a clinical study involving healthy volunteers. Similarly, no apparent effect of warfarin on levofloxacin absorption and disposition was observed. However, there have been reports during the postmarketing experience in patients that levofloxacin enhances the effects of warfarin. Elevations of the prothrombin time in the setting of concurrent warfarin and levofloxacin use have been associated with episodes of bleeding. Prothrombin time, International Normalized Ratio (INR), or other suitable anticoagulation tests should be closely monitored if levofloxacin is administered concomitantly with warfarin. Patients should also be monitored for evidence of bleeding [see Adverse Reactions (6. 2) and Patient Counseling Information (17) ]. Disturbances of blood glucose, including hyperglycemia and hypoglycemia, have been reported in patients treated concomitantly with fluoroquinolones and an antidiabetic agent. Therefore, careful monitoring of blood glucose is recommended when these agents are co-administered [see Warnings and Precautions (5. 13) Adverse Reactions (6. 1) Patient Counseling Information (17) The concomitant administration of a non-steroidal anti-inflammatory drug with a fluoroquinolone, including levofloxacin, may increase the risk of CNS stimulation and convulsive seizures [see Warnings and Precautions (5. 4) No significant effect of levofloxacin on the plasma concentrations, AUC, and other disposition parameters for theophylline was detected in a clinical study involving healthy volunteers. Similarly, no apparent effect of theophylline on levofloxacin absorption and disposition was observed. However, concomitant administration of other fluoroquinolones with theophylline has resulted in prolonged elimination half-life, elevated serum theophylline levels, and a subsequent increase in the risk of theophylline-related adverse reactions in the patient population. Therefore, theophylline levels should be closely monitored and appropriate dosage adjustments made when levofloxacin is co-administered. Adverse reactions, including seizures, may occur with or without an elevation in serum theophylline levels [see Warnings and Precautions (5. 4) No significant effect of levofloxacin on the peak plasma concentrations, AUC, and other disposition parameters for cyclosporine was detected in a clinical study involving healthy volunteers. However, elevated serum levels of cyclosporine have been reported in the patient population when co-administered with some other fluoroquinolones. Levofloxacin C max e max ½ No significant effect of levofloxacin on the peak plasma concentrations, AUC, and other disposition parameters for digoxin was detected in a clinical study involving healthy volunteers. Levofloxacin absorption and disposition kinetics were similar in the presence or absence of digoxin. Therefore, no dosage adjustment for levofloxacin or digoxin is required when administered concomitantly. No significant effect of probenecid or cimetidine on the C max 1/2 R Some fluoroquinolones, including levofloxacin, may produce false-positive urine screening results for opiates using commercially available immunoassay kits. Confirmation of positive opiate screens by more specific methods may be necessary.
Other Information
OVERDOSAGE
In the event of an acute overdosage, the stomach should be emptied. The patient should be observed and appropriate hydration maintained. Levofloxacin is not efficiently removed by hemodialysis or peritoneal dialysis. Levofloxacin exhibits a low potential for acute toxicity. Mice, rats, dogs and monkeys exhibited the following clinical signs after receiving a single high dose of levofloxacin: ataxia, ptosis, decreased locomotor activity, dyspnea, prostration, tremors, and convulsions. Doses in excess of 1500 mg/kg orally (approximately 10 or 19 times MRHD in mice and rats, respectively) and 250 mg/kg IV produced significant mortality (estimated to be greater than or equal to 50%) in rodents.
NONCLINICAL TOXICOLOGY
In a lifetime bioassay in rats, levofloxacin exhibited no carcinogenic potential following daily dietary administration for 2 years; the highest dose (100 mg/kg/day) was 1. 4 times the Maximum Recommended Human Dose (MRHD) (750 mg) after normalization for total body surface area. Levofloxacin did not shorten the time to tumor development of UV-induced skin tumors in hairless albino (Skh-1) mice at any levofloxacin dose level and was therefore not photo-carcinogenic under conditions of this study. Dermal levofloxacin concentrations in the hairless mice ranged from 25 to 42 mcg/g at the highest levofloxacin dose level (300 mg/kg/day) used in the photo-carcinogenicity study. By comparison, dermal levofloxacin concentrations in human subjects receiving 750 mg of levofloxacin averaged approximately 11. 8 mcg/g at C max Levofloxacin was not mutagenic in the following assays: Ames bacterial mutation assay ( S. typhimurium E. coli in vitro Levofloxacin caused no impairment of fertility or reproductive performance in rats at oral doses as high as 360 mg/kg/day, corresponding to 4. 2 times the MRHD and intravenous doses as high as 100 mg/kg/day, corresponding to 1. 2 times the MRHD after normalization for total body surface area. Levofloxacin and other quinolones have been shown to cause arthropathy in immature animals of most species tested [see Warnings and Precautions (5. 12) When tested in a mouse ear swelling bioassay, levofloxacin exhibited phototoxicity similar in magnitude to ofloxacin, but less phototoxicity than other quinolones. While crystalluria has been observed in some intravenous rat studies, urinary crystals are not formed in the bladder, being present only after micturition and are not associated with nephrotoxicity. In mice, the CNS stimulatory effect of quinolones is enhanced by concomitant administration of non-steroidal anti-inflammatory drugs. In dogs, levofloxacin administered at 6 mg/kg or higher by rapid intravenous injection produced hypotensive effects. These effects were considered to be related to histamine release. In vitro in vivo.
CLINICAL STUDIES
Adult patients with clinically and radiologically documented nosocomial pneumonia were enrolled in a multicenter, randomized, open-label study comparing intravenous levofloxacin (750 mg once daily) followed by oral levofloxacin (750 mg once daily) for a total of 7 to 15 days to intravenous imipenem/cilastatin (500 to 1000 mg every 6 to 8 hours daily) followed by oral ciprofloxacin (750 mg every 12 hours daily) for a total of 7 to 15 days. Levofloxacin-treated patients received an average of 7 days of intravenous therapy (range: 1 to 16 days); comparator-treated patients received an average of 8 days of intravenous therapy (range: 1 to 19 days). Pseudomonas aeruginosa S. aureus Table 9: Clinical Success Rates and Bacteriological Eradication Rates (Nosocomial Pneumonia) Pathogen N Levofloxacin No. (%) of N Imipenem/Cilastatin No. aureus dagger double dagger MSSA * 21 14 (66. 9) 19 13 (68. aeruginosa dagger 17 10 (58. 7) 17 5 (29. marcescens 11 9 (81. coli 12 10 (83. 3) 11 7 (63. pneumoniae double dagger 11 9 (81. influenzae 16 13 (81. 5) 15 14 (93. pneumoniae 4 3 (75)/3 (75) 7 5 (71. 1) Adult inpatients and outpatients with a diagnosis of community-acquired bacterial pneumonia were evaluated in 2 pivotal clinical studies. In the first study, 590 patients were enrolled in a prospective, multi-center, unblinded randomized trial comparing levofloxacin 500 mg once daily orally or intravenously for 7 to 14 days to ceftriaxone 1 to 2 grams intravenously once or in equally divided doses twice daily followed by cefuroxime axetil 500 mg orally twice daily for a total of 7 to 14 days. Patients assigned to treatment with the control regimen were allowed to receive erythromycin (or doxycycline if intolerant of erythromycin) if an infection due to atypical pathogens was suspected or proven. Clinical and microbiologic evaluations were performed during treatment, 5 to 7 days posttherapy, and 3 to 4 weeks posttherapy. Clinical success (cure plus improvement) with levofloxacin Chlamydophila pneumoniae, Mycoplasma pneumoniae Legionella pneumophila Table 10: Bacteriological Eradication Rates Across 2 Community Acquired Pneumonia Clinical Studies Pathogen No. Pathogens Bacteriological Eradication Rate (%) H. influenzae 55 98 S. pneumoniae 83 95 S. aureus 17 88 M. catarrhalis 18 94 H. parainfluenzae 19 95 K. pneumoniae 10 100 Community-Acquired Pneumonia Due to Multi-Drug Resistant Streptococcus pneumoniae Levofloxacin was effective for the treatment of community-acquired pneumonia caused by multi-drug resistant Streptococcus pneumoniae nd Table 11: Clinical and Bacterial Success Rates for Levofloxacin-Treated MDRSP in Community Acquired Pneumonia Patients (Population Valid for Efficacy) Screening Susceptibility Clinical Success Bacteriological Success * n/N dagger % n/N double dagger % Penicillin-resistant 16/17 94. 1 2 nd 31/32 96. 9 Macrolide-resistant 28/29 96. 6 Trimethoprim/ Sulfamethoxazole resistant 17/19 89. 5 Tetracycline-resistant 12/12 100 12/12 100 * dagger double dagger Not all isolates were resistant to all antimicrobial classes tested. Success and eradication rates are summarized in Table 12. Table 12: Clinical Success and Bacteriologic Eradication Rates for Resistant Streptococcus pneumoniae Type of Resistance Clinical Success Bacteriologic Eradication Resistant to 2 antibacterials 17/18 (94. 4%) 17/18 (94. 4%) Resistant to 3 antibacterials 14/15 (93. 3%) 14/15 (93. 3%) Resistant to 4 antibacterials 7/7 (100%) 7/7 (100%) Resistant to 5 antibacterials 0 0 Bacteremia with MDRSP 8/9 (89%) 8/9 (89%) To evaluate the safety and efficacy of the higher dose and shorter course of levofloxacin, 528 outpatient and hospitalized adults with clinically and radiologically determined mild to severe community-acquired pneumonia were evaluated in a double-blind, randomized, prospective, multicenter study comparing levofloxacin 750 mg, IV or orally, every day for five days or levofloxacin 500 mg IV or orally, every day for 10 days. Clinical success rates (cure plus improvement) in the clinically evaluable population were 90. 9% in the levofloxacin 750 mg group and 91. 1% in the levofloxacin 500 mg group. The 95% CI for the difference of response rates (levofloxacin 750 minus levofloxacin 500) was [-5. In the clinically evaluable population (31 to 38 days after enrollment) pneumonia was observed in 7 out of 151 patients in the levofloxacin 750 mg group and 2 out of 147 patients in the levofloxacin 500 mg group. Given the small numbers observed, the significance of this finding cannot be determined statistically. The microbiological efficacy of the 5-day regimen was documented for infections listed in Table 13. Table 13: Bacteriological Eradication Rates (Community-Acquired Pneumonia) S. pneumoniae 19/20 (95%) Haemophilus influenzae 12/12 (100%) Haemophilus parainfluenzae 10/10 (100%) Mycoplasma pneumoniae 26/27 (96%) Chlamydophila pneumoniae 13/15 (87%) Levofloxacin is approved for the treatment of acute bacterial sinusitis (ABS) using either 750 mg by mouth x 5 days or 500 mg by mouth once daily x 10 to 14 days. To evaluate the safety and efficacy of a high dose short course of levofloxacin, 780 outpatient adults with clinically and radiologically determined acute bacterial sinusitis were evaluated in a double-blind, randomized, prospective, multicenter study comparing levofloxacin 750 mg by mouth once daily for five days to levofloxacin 500 mg by mouth once daily for 10 days. Clinical success rates (defined as complete or partial resolution of the pre-treatment signs and symptoms of ABS to such an extent that no further antibiotic treatment was deemed necessary) in the microbiologically evaluable population were 91. 4% (139/152) in the levofloxacin 750 mg group and 88. 6% (132/149) in the levofloxacin 500 mg group at the test-of-cure (TOC) visit (95% CI [-4. 2, 10] for levofloxacin 750 mg minus levofloxacin 500 mg). Rates of clinical success by pathogen in the microbiologically evaluable population who had specimens obtained by antral tap at study entry showed comparable results for the five- and ten-day regimens at the test-of-cure visit 22 days post treatment (see Table 14). Table 14: Clinical Success Rate by Pathogen at the TOC in Microbiologically Evaluable Subjects Who Underwent Antral Puncture (Acute Bacterial Sinusitis) Pathogen Levofloxacin 750 mg x 5 days Levofloxacin 500 mg x 10 days Streptococcus pneumoniae* 25/27 (92. 6%) 26/27 (96. 3%) Haemophilus influenzae* 19/21 (90. 5%) 25/27 (92. 6%) Moraxella catarrhalis* 10/11 (90. 9%) 13/13 (100%) * Note: Forty percent of the subjects in this trial had specimens obtained by sinus endoscopy. The efficacy data for subjects whose specimen was obtained endoscopically were comparable to those presented in the above table. Three hundred ninety-nine patients were enrolled in an open-label, randomized, comparative study for complicated skin and skin structure infections. The patients were randomized to receive either levofloxacin 750 mg once daily (IV followed by oral), or an approved comparator for a median of 10 +/- 4. As is expected in complicated skin and skin structure infections, surgical procedures were performed in the levofloxacin and comparator groups. Surgery (incision and drainage or debridement) was performed on 45% of the levofloxacin-treated patients and 44% of the comparator-treated patients, either shortly before or during antibiotic treatment and formed an integral part of therapy for this indication. Adult patients with a clinical diagnosis of prostatitis and microbiological culture results from urine sample collected after prostatic massage (VB 3 Table 15: Bacteriological Eradication Rates (Chronic Bacterial Prostatitis) Pathogen Levofloxacin (N = 136) Ciprofloxacin (N = 125) N Eradication N Eradication * Eradication rates shown are for patients who had a sole pathogen only; mixed cultures were excluded. coli 15 14 (93. 3%) 11 9 (81. faecalis 54 39 (72. 2%) 44 33 (75%) S. epidermidis* 11 9 (81. 8%) 14 11 (78. 6%) Eradication rates for S. epidermidis To evaluate the safety and efficacy of the higher dose and shorter course of levofloxacin, 1109 patients with cUTI and AP were enrolled in a randomized, double-blind, multicenter clinical trial conducted in the U. from November 2004 to April 2006 comparing levofloxacin 750 mg IV or orally once daily for 5 days (546 patients) with ciprofloxacin 400 mg IV or 500 mg orally twice daily for 10 days (563 patients). Patients with AP complicated by underlying renal diseases or conditions such as complete obstruction, surgery, transplantation, concurrent infection or congenital malformation were excluded. Efficacy was measured by bacteriologic eradication of the baseline organism(s) at the post-therapy visit in patients with a pathogen identified at baseline. The post-therapy (test-of-cure) visit occurred 10 to 14 days after the last active dose of levofloxacin and 5 to 9 days after the last dose of active ciprofloxacin. Table 16: Bacteriological Eradication at Test-of-Cure * 5 dagger 5 Levofloxacin Ciprofloxacin Overall Difference n/N % n/N % Levofloxacin- mITT Population* Overall (cUTI or AP) 252/333 75. 7 239/318 75. 1) cUTI 168/230 73 157/213 73. 7 AP 84/103 81. 6 82/105 78. 1 Microbiologically Evaluable Population dagger Overall (cUTI or AP) 228/265 86 215/241 89. 5] cUTI 154/185 83. 2 144/165 87. 3 AP 74/80 92. 4 Microbiologic eradication rates in the Microbiologically Evaluable population at TOC for individual pathogens recovered from patients randomized to levofloxacin treatment are presented in Table 17. Table 17: Bacteriological Eradication Rates for Individual Pathogens Recovered From Patients Randomized to Levofloxacin 750 mg QD for 5 Days Treatment Pathogen Bacteriological % * The predominant organism isolated from patients with AP was E. coli Escherichia coli* 155/172 90 Klebsiella pneumoniae 20/23 87 Proteus mirabilis 12/12 100 To evaluate the safety and efficacy of the 250 mg dose, 10 day regimen of levofloxacin, 567 patients with uncomplicated UTI, mild-to-moderate cUTI, and mild-to-moderate AP were enrolled in a randomized, double-blind, multicenter clinical trial conducted in the U. from June 1993 to January 1995 comparing levofloxacin 250 mg orally once daily for 10 days (285 patients) with ciprofloxacin 500 mg orally twice daily for 10 days (282 patients). Patients with a resistant pathogen, recurrent UTI, women over age 55 years, and with an indwelling catheter were initially excluded, prior to protocol amendment which took place after 30% of enrollment. Microbiological efficacy was measured by bacteriologic eradication of the baseline organism(s) at 1 to 12 days post-therapy in patients with a pathogen identified at baseline. Table 18: Bacteriological Eradication Overall (cUTI or AP) at Test-Of-Cure* * 1 to 9 days posttherapy for 30% of subjects enrolled prior to a protocol amendment; 5 to 12 days posttherapy for 70% of subjects. dagger double dagger Levofloxacin Ciprofloxacin n/N % n/N % mITT Population dagger 174/209 83. 3 184/219 84 Microbiologically Evaluable Population double dagger 164/177 92. 7 159/171 93 The effectiveness of levofloxacin for this indication is based on plasma concentrations achieved in humans, a surrogate endpoint reasonably likely to predict clinical benefit. Levofloxacin has not been tested in humans for the post-exposure prevention of inhalation anthrax. The mean plasma concentrations of levofloxacin associated with a statistically significant improvement in survival over placebo in the rhesus monkey model of inhalational anthrax are reached or exceeded in adult and pediatric patients receiving the recommended oral and intravenous dosage regimens [see Indications and Usage (1. 13) Dosage and Administration (2. 2) 0-24 [see Clinical Pharmacology (12. 3) [see Dosage and Administration (2. 2) [see Warnings and Precautions (5. 12) Use in Specific Populations (8. 4) 50 6 50 B. anthracis max 0-24 Efficacy studies of levofloxacin could not be conducted in humans with pneumonic plague for ethical and feasibility reasons. Therefore, approval of this indication was based on an efficacy study conducted in animals. [see Indications and Usage (1. 14) Dosage and Administration (2. 2) 50 50 Yersinia pestis Y. pestis 0-24 o Y.
MEDICATION GUIDE
Levofloxacin (lee'''' voe flox'' a sin) What is the most important information I should know about levofloxacin tablets? Levofloxacin tablets, a fluoroquinolone antibiotic, can cause serious side effects. Some of these serious side effects can happen at the same time and could result in death. you should stop taking levofloxacin tablets immediately and get medical help right away. 1. Tendon rupture or swelling of the tendon (tendinitis). Tendon problems can happen in people of all ages who take levofloxacin tablets. Some tendon problems include pain swelling tears and swelling of tendons including the back of the ankle (Achilles), shoulder, hand, or other tendon sites The risk of getting tendon problems while you take levofloxacin tablets are higher if you: are over 60 years of age are taking steroids (corticosteroids) have had a kidney, heart or lung transplant Tendon problems can happen in people who do not have the above risk factors when they take levofloxacin tablets. Other reasons that can increase your risk of tendon problems can include: physical activity or exercise kidney failure tendon problems in the past, such as in people with rheumatoid arthritis (RA) Stop taking levofloxacin tablets immediately and get medical help right away at the first sign of tendon pain, swelling or inflammation. Avoid exercise and using the affected area. The most common area of pain and swelling is the Achilles tendon at the back of your ankle. This can also happen with other tendons. You may need a different antibiotic that is not a fluoroquinolone to treat your infection. Tendon rupture can happen while you are taking or after you have finished taking levofloxacin tablets. Tendon ruptures can happen within hours or days of taking levofloxacin tablets and have happened up to several months after people have finished taking their fluoroquinolone. Stop taking levofloxacin tablets immediately and get medical help right away if you get any of the following signs or symptoms of a tendon rupture: hear or feel a snap or pop in a tendon area bruising right after an injury in a tendon area unable to move the affected area or bear weight The tendon problems may be permanent. 2. Changes in sensation and possible nerve damage (Peripheral Neuropathy). pain burning tingling numbness weakness The nerve damage may be permanent. 3. Central Nervous System (CNS) effects. seizures hear voices, see things, or sense things that are not there (hallucinations) feel restless or agitated tremors feel anxious or nervous confusion depression reduced awareness of surroundings trouble sleeping nightmares feel lightheaded or dizzy feel more suspicious (paranoia) suicidal thoughts or acts headaches that will not go away, with or without blurred vision memory problems false or strange thoughts or beliefs (delusions) The CNS changes may be permanent. 4. Worsening of myasthenia gravis (a problem that causes muscle weakness). What are levofloxacin tablets? nosocomial pneumonia community acquired pneumonia skin infections, complicated and uncomplicated chronic prostate infection inhalation anthrax germs plague urinary tract infections, complicated and uncomplicated acute kidney infection (pyelonephritis) acute worsening or chronic bronchitis acute sinus infection Studies of levofloxacin tablets for use in the treatment of plague and anthrax were done in animals only, because plague and anthrax could not be studied in people. Who should not take levofloxacin tablets? Do not take levofloxacin tablets Before you take levofloxacin tablets, tell your healthcare provider about all of your medical conditions, including if you: have tendon problems. Levofloxacin tablets should not be used in people who have a history of tendon problems. have a problem that causes muscle weakness (myasthenia gravis). Levofloxacin tablets should not be used in people who have a known history of myasthenia gravis. have a history of mental health problems, including depression. have central nervous system problems such as seizures (epilepsy). have nerve problems. Levofloxacin tablets should not be used in people who have a history of a nerve problem called peripheral neuropathy. have or anyone in your family has an irregular heartbeat, especially a condition called “QT prolongation." have low blood potassium (hypokalemia). have bone problems. have joint problems including rheumatoid arthritis (RA). have kidney problems. You may need a lower dose of levofloxacin tablets if your kidneys do not work well. have liver problems. have diabetes or problems with low blood sugar (hypoglycemia). are pregnant or plan to become pregnant. It is not known if levofloxacin tablets will harm your unborn child. are breastfeeding or plan to breastfeed. Levofloxacin tablets passes into your breast milk. You should not breastfeed during treatment with levofloxacin tablets and for 2 days after taking your last dose of levofloxacin tablets. You may pump your breast milk and throw it away during treatment with levofloxacin tablets and for 2 days after taking your last dose of levofloxacin tablets. If you are taking levofloxacin tablets for inhalational anthrax, you and your healthcare provider should decide whether you can continue breastfeeding while taking levofloxacin tablets. Tell your healthcare provider about all the medicines you take, Especially tell your healthcare provider if you take: a steroid medicine. an anti-psychotic medicine. a tricyclic antidepressant. a water pill (diuretic). certain medicines may keep levofloxacin tablets from working correctly. Take levofloxacin tablets either 2 hours before or 2 hours after taking these medicines or supplements: an antacid, multivitamin, or other medicines or supplements that have magnesium, aluminum, iron, or zinc sucralfate (Carafate registered didanosine (Videx registered registered a blood thinner (warfarin, Coumadin, Jantoven). an oral anti-diabetes medicine or insulin. an NSAID (Non-Steroidal Anti-Inflammatory Drug). Many common medicines for pain relief are NSAIDs. Taking an NSAID while you take levofloxacin tablets or other fluoroquinolones may increase your risk of central nervous system effects and seizures. theophylline (Theo-24 registered registered registered registered registered a medicine to control your heart rate or rhythm (antiarrhythmics). Ask your healthcare provider if you are not sure if any of your medicines are listed above. Know the medicines you take. Keep a list of your medicines and show it to your healthcare provider and pharmacist when you get a new medicine. How should I take levofloxacin tablets? Take levofloxacin tablets exactly as your healthcare provider tells you to take them. Take levofloxacin tablets at the same time each day. Drink plenty of fluids while you take levofloxacin tablets. Levofloxacin tablets can be taken with or without food. If you miss a dose of levofloxacin tablets and it is: 8 hours or more less than 8 hours Do not skip any doses of levofloxacin tablets or stop taking them, even if you begin to feel better, until you finish your prescribed treatment unless: you have tendon problems. See “What is the most important information I should know about levofloxacin tablets?”. you have a nerve problem. See “ What is the most important information I should know about levofloxacin tablets? you have a central nervous system problem. See “ What is the most important information I should know about levofloxacin tablets? you have a serious allergic reaction. See “What are the possible side effects of levofloxacin tablets?”. your healthcare provider tells you to stop taking levofloxacin tablets. Taking all of your levofloxacin tablets doses will help make sure that all of the bacteria are killed. Taking all of your levofloxacin tablets doses will help you lower the chance that the bacteria will become resistant to levofloxacin tablets. If your infection does not get better while you take levofloxacin tablets, it may mean that the bacteria causing your infection may be resistant to levofloxacin tablets. If your infection does not get better, call your healthcare provider. If your infection does not get better, levofloxacin tablets and other similar antibiotic medicines may not work for you in the future. If you take too much levofloxacin, call your healthcare provider or get medical help right away. What should I avoid while taking levofloxacin tablets? Levofloxacin tablets can make you feel dizzy and lightheaded. Do not Avoid sunlamps, tanning beds, and try to limit your time in the sun. Levofloxacin tablets can make your skin sensitive to the sun (photosensitivity) and the light from sunlamps and tanning beds. You could get severe sunburn, blisters or swelling of your skin. If you get any of these symptoms while you take levofloxacin tablets, call your healthcare provider right away. You should use sunscreen and wear a hat and clothes that cover your skin if you have to be in sunlight. What are the possible side effects of levofloxacin tablets? Levofloxacin tablets may cause serious side effects, including: See “What is the most important information I should know about levofloxacin tablets?” Serious allergic reactions hives trouble breathing or swallowing swelling of the lips, tongue, face throat tightness, hoarseness rapid heartbeat faint skin rash Skin rash may happen in people taking levofloxacin tablets, even after only 1 dose. Stop taking levofloxacin tablets at the first sign of a skin rash and immediately call your healthcare provider. Skin rash may be a sign of a more serious reaction to levofloxacin tablets. Liver damage (hepatotoxicity): nausea or vomiting stomach pain fever weakness pain or tenderness in the upper right side of your stomach-area itching unusual tiredness loss of appetite light colored bowel movements dark colored urine yellowing of your skin or the whites of your eyes Stop taking levofloxacin tablets and tell your healthcare provider right away if you have yellowing of your skin or white part of your eyes, or if you have dark urine. These can be signs of a serious reaction to levofloxacin tablets (a liver problem). Aortic aneurysm and dissection: Intestine infection ( Clostridium difficile Serious heart rhythm changes (QT prolongation and torsades de pointes). who are elderly with a family history of prolonged QT interval with low blood potassium (hypokalemia) who take certain medicines to control heart rhythm (antiarrhythmics) Joint Problems. Changes in blood sugar. Sensitivity to sunlight (photosensitivity). “What should I avoid while taking levofloxacin tablets?” The most common side effects of levofloxacin tablets include: nausea headache diarrhea insomnia constipation dizziness In children 6 months and older who take levofloxacin tablets to treat anthrax disease or plague, vomiting is also common. Levofloxacin tablets may cause false-positive urine screening results for opiates when testing is done with some commercially available kits. A positive result should be confirmed using a more specific test. These are not all the possible side effects of levofloxacin tablets. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. How should I store levofloxacin tablets? Store levofloxacin tablets at room temperature between 20° to 25°C (68° to 77°F). Keep levofloxacin tablets in a tightly closed container. General information about the safe and effective use of levofloxacin tablets. What are the ingredients in levofloxacin tablets? Active ingredient: Inactive ingredients: Repackaged By / Distributed By: RemedyRepack Inc. 625 Kolter Drive, Indiana, PA 15701 (724) 465-8762
Manufacturer
REMEDYREPACK INC.